Clene Inc. - Press Releases

Year

Clene Appoints Neurology Expert to Executive Team

SALT LAKE CITY, March 16, 2023 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today

March 16, 2023

PDF Version

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

Amyotrophic lateral sclerosis (ALS): Significant survival benefits demonstrated across two ALS clinical trials, along with clinical improvements as early as six months CNM-Au8 ® associated with 74% lower risk of ALS clinical worsening events at six months supporting a survival benefit in the HEALEY

March 13, 2023

PDF Version

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

CNM-Au8 associated with a 74% lower risk (lower hazard ratio) of ALS clinical worsening, which included death, non-invasive ventilation >22 hours per day, tracheostomy, or feeding tube placement (p = 0.035) CNM-Au8 associated with a 98% lower risk of death or permanent assisted ventilation (p=

March 9, 2023

PDF Version

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

Webcast set for 7:30 a.m. ET on March 9 SALT LAKE CITY, March 08, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment

March 8, 2023

PDF Version

Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today

March 7, 2023

PDF Version

New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial

Significant preservation of function (ALSFRS-R) from randomization to 48 weeks (p=0.0159) Significant preservation of function (ALSFRS-R) during the long-term open-label extension (OLE) week 24 to 120 weeks from randomization (p=0.0057) Significantly reduced risk of ALS clinical worsening by 52%

March 6, 2023

PDF Version

Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System

Positive clinical results demonstrated in stable relapsing multiple sclerosis patients adjunctive to immunomodulatory disease modifying therapy was previously reported Updated Visual Evoked Potential (VEP) findings provide evidence of improved information signaling from the eye to the brain’s

February 27, 2023

PDF Version

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

MRI results reinforce the clinical neurological improvements previously reported MRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effect MRI results consistently favor CNM-Au8 improvement of neuronal integrity and myelin improvement, showing

February 13, 2023

PDF Version

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Communications Inc.’s

January 11, 2023

PDF Version